42516-28-9

Usage

Uses

Used in Pharmaceutical Industry:
TRIETHYL 4-PHOSPHONOCROTONATE is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing ones.
Used in Agrochemical Industry:
TRIETHYL 4-PHOSPHONOCROTONATE is used as a building block in the production of agrochemicals, aiding in the creation of effective pesticides and other agricultural chemicals.
Used in Fine Chemicals Industry:
TRIETHYL 4-PHOSPHONOCROTONATE is used as a building block for the synthesis of various fine chemicals, enhancing the quality and performance of specialty chemicals.
Used as a Solvent:
TRIETHYL 4-PHOSPHONOCROTONATE is used as a solvent in organic synthesis, facilitating various chemical reactions and improving the overall process efficiency.
Used as an Intermediate in Organic Synthesis:
TRIETHYL 4-PHOSPHONOCROTONATE is used as an intermediate in organic synthesis, participating in a variety of chemical reactions and contributing to the formation of complex organic molecules.
It is important to handle TRIETHYL 4-PHOSPHONOCROTONATE with care due to its potential hazards, and proper safety precautions should be observed when working with it.

InChI:InChI=1/C10H19O5P/c1-4-13-10(11)8-7-9-16(12,14-5-2)15-6-3/h7-8H,4-6,9H2,1-3H3

Upstream product

• 623-70-1 ethyl (E)-crotonate 
• 78-40-0 triethyl phosphate 
• 37746-78-4 4-bromo-trans-crotonic acid ethyl ester 
• 1067-87-4 Diethyl allylphosphonate 
• 140-88-5 ethyl acrylate 
• 6065-32-3 4-bromocrotonic ethyl ester 
• 122-52-1 triethyl phosphite 
• 1606-75-3 (2-oxoethyl)phosphonic acid diethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 10236-06-3 5-Methyl-hexa-1,3-dien-1-carbonsaeure-ethylester 
• 1110610-35-9 5-phenyl-hexa-2t,4ξ-dienoic acid ethyl ester 
• 119011-82-4 ethyl 4-(2-methylcyclohexylidene)but-2-enoate 
• 233609-19-3 (2E,4E)-(R)-6-Methoxy-8-(4-methoxy-benzyloxy)-octa-2,4-dienoic acid ethyl ester 
• 174390-10-4 (2E,4Z)-5-[3-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-phenyl]-hexa-2,4-dienoic acid ethyl ester 
• 174258-98-1 (E,E)-5-(3-[5-methyl-2-phenyl-oxazol-4-ylmethoxy]-phenyl)-hexa-2,4-dienoic acid ethyl ester 
• 159017-91-1 ethyl (2E,4E)-5-(4-isopropoxyphenyl)-2,4-pentadienoate 
• 60347-68-4 ethyl all-E-13-demethylretinoate 
• 757240-62-3 ethyl 9Z-13-demethylretinoate 
• 16913-44-3 (2E,4E)-5-(3,4-Dichloro-phenyl)-penta-2,4-dienoic acid ethyl ester 
• 910661-40-4 ethyl (E,E)-5-(2-bromophenyl)penta-2,4-dienoate 
• 183800-77-3 (2E,4E)-ethyl 5-(4-(trifluoromethyl)phenyl)penta-2,4-dienoate 
• 316362-81-9 ethyl trans-4-(N-benzyl-4'-piperidinyliden)-2-butenoate 
• 7508-09-0 5-(3,4-dimethoxyphenyl)-2,4-pentadienic acid 

Relevant academic research and scientific papers

Stereoselective syntheses of sanshool derivatives

Accessible methods for the syntheses of some representatives of tetradecapentaenoic acid derivatives using organophosphorus reagents and highly stereoselective properties of phosphonate carbanions were developed.

Total Synthesis of δ-Sanshool and Analogues Thereof

Two simple synthetic approaches were developed for the total synthesis of δ-sanshool, an isobutylamide characterized by a C14 pentaunsaturated chain with all trans double bonds and proposed as a promising lead for the treatment of type-1 diabetes due to its dual activity on cannabinoid (CB) receptors. The syntheses are based on a suitably protected core fragment derived from 1,4-butanediol. These strategies also enable the preparation of small libraries of chemical analogues modified at either the polyunsaturated alkyl chain or the amidic head for use in SAR studies.

Synthesis of 2,3-dihydroxy-3-(N-substituted carbamoyl)propylphosphonic acid derivatives as hybrid DOXP-fosmidomycin analogues

A six-step synthetic pathway has been established to access a series of racemic 2,3-dihydroxy-3-(N-substituted carbamoyl)propylphosphonic acid derivatives, designed to contain structural features common to both the natural substrate 1-deoxy-D-xylulose 5-p

Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists

Synthetic indole cannabinoids characterized by a 2′,2′-dimethylindan-5′-oyl group at the indole C3 position constitute a new class of ligands possessing high affinity for human CB2 receptors at a nanomolar concentration and a good selectivity index. Start

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity

Estrogen receptor α (ERα) is an important target for the design of drugs such as tamoxifen (2a) and fulvestrant (5). Three series of ER-ligands based on the benzoxepin scaffold structure were synthesized: series I containing an acrylic acid, series II with an acrylamide, and series III with a saturated carboxylic acid substituent. These compounds were shown to be high affinity ligands for the ER with nanomolar IC50 binding values. Series I acrylic acid ligands were generally ERα selective. In particular, compound 13e featuring a phenylpenta-2,4-dienoic acid substituent was shown to be antiproliferative and downregulated ERα and ERβ expression in MCF-7 breast cancer cells. Interestingly, from series III, the phenoxybutyric acid derivative compound 22 was not antiproliferative and selectively downregulated ERβ. A docking study of the benzoxepin ligands was undertaken. Compound 13e is a promising lead for development as a clinically relevant SERD, while compound 22 will be a useful experimental probe for helping to elucidate the role of ERβ in cancer cells.

Total synthesis of Carpatamides A–D

A synthetic strategy was developed for the synthesis of the common core structure of Carpatamides A–D. The total synthesis of Carpatamides A and C was completed in 6 steps and of Carpatamides B and D in 7 steps, by employing the Wittig olefination, olefin

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Cross-metathesis reaction of functionalized and substituted olefins using group 8 transition metal carbene complexes as metathesis catalysts

The invention pertains to the use of Group 8 transition metal carbene complexes as catalysts for olefin cross-metathesis reactions. In particular, ruthenium and osmium alkylidene complexes substituted with an N-heterocyclic carbene ligand are used to catalyze cross-metathesis reactions to provide a variety of substituted and functionalized olefins, including phosphonate-substituted olefins, directly halogenated olefins, 1,1,2-trisubstituted olefins, and quaternary allylic olefins. The invention further provides a method for creating functional diversity using the aforementioned complexes to catalyze cross-metathesis reactions of a first olefinic reactant, which may or may not be substituted with a functional group, with each of a plurality of different olefinic reactants, which may or may not be substituted with functional groups, to give a plurality of structurally distinct olefinic products. The methodology of the invention is also useful in facilitating the stereoselective synthesis of 1,2-disubstituted olefins in the cis configuration.

NOVEL PIPERINE DERIVATIVES AND USES THEREOF

The present invention provides novel piperine derivatives. The present pharmaceutical or food composition containing a piperine derivative as an active ingredient is very effective in preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. Piperine derivatives of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for metabolic syndrome selected from the group consisting of obesity, diabetes, hyperlipidemia, fatty liver and insulin resistance syndrome, and also suppress the differentiation of progenitor cells and reduce the accumulation of triglycerides.

NOVEL PIPERINE DERIVATIVE AND USE THEREFOR

The present invention provides novel piperine derivatives. The present pharmaceutical or food composition containing a piperine derivative as an active ingredient is very effective in preventing or treating metabolic diseases including obesity, diabetes,